Gambardella Alessio
Dermatology Unit, University of Campania, Naples, Italy.
Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):11-16. doi: 10.1159/000501993. eCollection 2019 Sep-Dec.
Although available data are conflicting, psoriasis seems to be associated with an increased baseline risk of malignancy. In addition, some antipsoriatic systemic treatments have been associated with risk of malignancy. There is not enough data on the association of interleukin (IL)-17 and IL-23 inhibitors with malignancy rate, but there have been no cases reported so far. Secukinumab is a recombinant human monoclonal immunoglobulin G1/κ antibody that selectively targets IL-17A; it was demonstrated to be effective and safe for the treatment of moderate to severe psoriasis that may be appropriate in frail subjects, as patients previously experienced malignancy, as in the case reported.
尽管现有数据存在矛盾，但银屑病似乎与恶性肿瘤的基线风险增加有关。此外，一些银屑病全身治疗与恶性肿瘤风险相关。关于白细胞介素（IL）-17和IL-23抑制剂与恶性肿瘤发生率之间的关联，目前尚无足够数据，但迄今为止尚未有相关病例报告。司库奇尤单抗是一种重组人单克隆免疫球蛋白G1/κ抗体，可选择性靶向IL-17A；已证明其对治疗中度至重度银屑病有效且安全，对于身体虚弱的患者、既往有恶性肿瘤病史的患者（如本报告病例）可能适用。
